Previous 10 | Next 10 |
Brooklyn Immunotherapeutics (NASDAQ:BTX): Q3 GAAP EPS of -$1.70 misses by $1.62. Cash of $24.4M. Press Release For further details see: Brooklyn Immunotherapeutics EPS misses by $1.62
NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and...
NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood diso...
NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, a...
NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood dis...
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorde...
Brooklyn ImmunoTherapeutics Inc. (AMX:BTX) is one of today's biggest movers, down 17.5% to $9.86. Over the past year, Brooklyn ImmunoTherapeutics Inc. has traded in a range of $3.10 to $80.67 and is now at $9.86, 218% above that low. Receive IBN Spotlights - "Bite Size" Small, Mid and ...
Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 Cleanroom Facility in Cambridge, Massachusetts PR Newswire CAMBRIDGE, Mass. , Sept. 15, 2021 /PRNewswire/ -- Factor Bioscience Inc., a biotechnology company headquartered in Cambrid...
BROOKLYN, N.Y., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics , Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood d...
NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorde...
News, Short Squeeze, Breakout and More Instantly...
Brooklyn ImmunoTherapeutics Inc. Company Name:
BTX Stock Symbol:
NYSE Market:
Brooklyn ImmunoTherapeutics Inc. Website:
New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Company’s...
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnos...
SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology, today ann...